The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
Tandem Diabetes Care, Inc.
350 participants
Mar 3, 2026
OBSERVATIONAL
Conditions
Summary
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.
Eligibility
Inclusion Criteria10
- Clinician-confirmed type 1 diabetes and for whom the site has initiated the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with a Dexcom G6 or G7 CGM sensor.
- Age ≥ 6 years at enrollment.
- Using an insulin approved for use in the pump.
- Ability for patient or parent/guardian to respond to alerts and alarms, and to provide basic diabetes self-management.
- Reside full-time in mainland France.
- Have an email address and mobile phone number
- Participant or participant's parent/guardian has read and understood the information notice and has agreed to participate in the study. This includes agreeing to :
- use Control-IQ technology, and to continue use for at least 12 consecutive months after study enrollment.
- the reuse of their clinical data including HbA1c results, obtained at most 4 months prior to enrollment, and as available according to the standard of care during the next 12 months.
- complete questionnaires per the study protocol.
Exclusion Criteria2
- A medical or other condition, or medications being taken that, in the investigator's judgement would be a safety concern for participation in the study.
- Patients considered vulnerable under French law.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants enrolled in the study will start use of the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with Dexcom G6 or Dexcom G7, and be followed for 12 months.
Locations(21)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07211126